Ruti Aga Handed Six-Year Ban: AIU Comes Down Hard After Family Member Issues Forged Prescription

Ethiopian marathon runner Ruti Aga has been suspended for six years by the Athletics Integrity Unit (AIU). According to a statement issued on Thursday, the 32-year-old has been found guilty on two separate counts: a two-year sanction for the presence of the prohibited substance methylprednisolone, and a four-year sanction for tampering with the investigation by submitting a forged document and giving misleading information. The two periods combine into a six-year ban, effective from 10 September — the same date her provisional suspension began. The statement as quoted does not specify the year, but the references to a Thursday release and a 10 September provisional suspension make clear the case is recent.

The case originates from a half marathon in China in March, which Aga won. A sample taken after that race returned an adverse finding for methylprednisolone. The available report does not record the name of the race, the venue, her finishing time or the quality of the field — so no performance judgement can be drawn. What is certain is that she won it, which implies a World Athletics Label-tier road race with an elite women's field and in-competition testing.

A significant technical error about the substance

Media reports have described methylprednisolone as a 'prohibited steroid'. That is imprecise. Methylprednisolone is a glucocorticoid, falling under class S9 of the WADA Prohibited List — not an anabolic steroid, which is class S1. And the distinction is not merely semantic. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only when administered by injection, oral or rectal routes. The direct consequence is that the entire case turns not on 'steroid use' but on the route of administration and its timing relative to competition. A therapeutic knee injection is entirely legal out-of-competition; it becomes a violation only if residues are present in an in-competition sample.

That is precisely where a legitimate defence could have been built. For a distance runner, intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice. The clinical plausibility of the explanation is exactly why real records would have defended it. What happened instead is the opposite — and that fact became decisive.

Three layers of verification failure

The AIU investigation found that the 'doctor' who issued the prescription was a family member with no medical registration, who claimed to have used 'an old prescription pad from a former workplace'. The investigation further established that the clinic named on the document did not exist. Verification failed at three independent points: no clinic, no registered practitioner, and a clinic that explicitly disowned the pad. This is not a procedural lapse but deliberately fabricated evidence.

It also matters that the four-year sanction arises from an interview, not from a document alone — it rests on statements made under questioning. Language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring point of contention, but in this case the documentary contradictions are so stark that such an argument would not be effective.

Career context

Aga's competitive record is substantial in its own right. Public records indicate a personal best of roughly 2:18:34, set at the 2026 Berlin Marathon where she finished second; she won the 2026 Tokyo Marathon. She also has three second-place finishes at World Marathon Majors. These figures rest on independent verification and are not stated in the original report, so they should be read with that caveat — but for a 2:18 to 2:20 marathoner, this is a high-calibre profile.

Importantly, the violation is anchored to a later March race. Absent a finding of earlier use, results before that date are not automatically annulled — including the 2026 Tokyo title. The report does not clarify the scope of the disqualification. Under standard AIU practice, however, the result and prize money from the competition where the sample was collected are almost certain to be voided.

Career impact: what a return at 38 means

A six-year ban at 32 is, in practical terms, a lifetime ban for a distance runner. By the time it expires she will be around 38. The depth of Ethiopian women's marathon running is such that even a 2:18 performer is not automatically selected for the national team — and for a 38-year-old with a doping record, selection is effectively implausible. The ban removes her entirely from the 2028 Olympic cycle and ends her elite career.

The sharp conclusion is this: the substance did not make this case career-terminal; the athlete's own conduct did. With transparent medical records, a substantially reduced period could have been argued instead of two years, and no tampering charge would have arisen at all.

The systemic problem: a governance vacuum

The central lesson of this case is administrative, not athletic. The knee injury was presumably real and serious — chronic knee pathology is a known load-bearing failure mode in high-volume marathoners. But treatment should have come from a credentialed team physician, not a family member writing on an old pad. That is a clear signal that no formal medical structure existed around the athlete.

Had the injury been properly documented, two legitimate routes were open: a Therapeutic Use Exemption, or observance of WADA's route-specific washout period. Neither appears to have been pursued. When no valid defensive pathway was available, documents were fabricated — the product of a governance gap, and more systemic than individual.

China's label races: income and scrutiny colliding

There is another dimension. For East African marathoners, Asian label races between Majors have functioned as a lucrative, low-race-count income tier — relatively few appearances, good fees. That same tier is now one of the AIU's highest-yield testing grounds. The appearance-fee economy and the testing economy are colliding in the same races, and Aga's case is a direct illustration of that collision.

No measurable effect on the competitive landscape

From a sporting standpoint, Ethiopia's women's marathon capacity is unaffected. Aga's three Major second places were commercial-tier results, not global championship medals. In a country with world-record-class performers, the absence of one 32-year-old does not alter selection arithmetic. The real shift is at the level of enforcement: tampering charges are clustering in AIU road-running cases, which suggests the enforcement frontier has moved from detection to document verification.

Sanction architecture and appeal

Read the numbers and the structure is standard, not exceptional. Two years for the presence violation — typically imposed where intent is not proven for a Specified Substance — and four years for tampering, the Code's standard sanction. The arithmetic implies the panel rejected the no-significant-fault mitigation. Backdating to the provisional suspension is a procedural benefit, not a real reduction.

An appeal to CAS is open, typically within about 21 days of the reasoned decision. But the forgery finding is document-based and hard to overturn.

A broader question should be left open too: a six-year ban for a glucocorticoid with no proven endurance benefit will be cited from both directions — by some as evidence of AIU rigour, by others as evidence of disproportionate enforcement against African road runners.

What remains unclear

The year of the March race, the year the ban began, the precise scope of disqualification and the annulment of the March result are none of them explicitly stated in the available statement. No official response from the Ethiopian federation is quoted either. Until those details are public, conclusions should be read within these limits.